Yisheng Biotechnology (01061.HK) announced its interim results, with a profit of approximately HKD 111 million, a decrease of 32.2% compared to the same period last year.

Zhitong Finance APP News, ESUN Biotechnology (01061.HK) announced its interim results for 2026, with a revenue of approximately HKD 785 million, a year-on-year decrease of 10.5%; profit of approximately HKD 111 million, a year-on-year decrease of 32.2%; earnings per share of 19.53 HK cents, and a proposed interim dividend of 5 HK cents per share.